GlobeNewswire Inc | Sep 2, 2020 07:00AM EDT

September 02, 2020

DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced its participation in the following upcoming investor conferences:

-- 2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, September 10, 2020 Time: 12:40 1:10 PM ET -- H.C. Wainwright Annual Global Investment Conference Date: Monday, September 14, 2020 Time: 1:30 1:50 PM ET -- Morgan Stanley Global Healthcare Conference Date: Thursday, September 17, 2020 Time: 8:45 9:15 AM ET

Live webcasts of each presentation will be accessible on the Companys website, www.PrecisionBiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.PrecisionBioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Companys pipeline consists of multiple off-the-shelf CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. Elo Life Systems is a wholly-owned subsidiary of Precision BioSciences also using ARCUS to benefit human health and wellness with novel food products that enhance the nutrition and diversity of global food supply. For more information about Precision BioSciences please visitwww.precisionbiosciences.com.

Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.messier@precisionbiosciences.com

Josh Rappaport Stern Investor Relationsjosh.rappaport@sternir.com